IO Biotech
Clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer.
Market cap
$92.9m
Enterprise value
$58m
Share price
$1.39 IOBT
Company register number
36474483
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | €57.5m | Post IPO Debt | |
| Total Funding | 000k | ||
Heartcore Capital(exited)
Lundbeckfonden Ventures(exited)
Novo Nordisk(exited)
Novo Ventures(exited)
Sunstone Life Science Ventures(exited)
Novo Holdings(exited)
Lundbeckfonden(exited)
Avoro Capital Advisors(exited)
RA Capital Management(exited)
Samsara BioCapital(exited)
Eurazeo(exited)
PFM Health Sciences(exited)
Soleus Capital(exited)
Eir Ventures(exited)
Serrado Capital(exited)
Novo Seeds(exited)
Lundbeckfonden Emerge(exited)
Kurma Partners(exited)
Vivo Capital(exited)
HBM Partners(exited)
HBM Healthcare Investments(exited)
Armistice Capital(exited)
Stonepine Capital Management(exited)
Logos Capital(exited)
Altamont Pharmaceutical Holdings(exited)
Marshall Wace(exited)
Red Hook Management(exited)
Pivotal Life Sciences(exited)
University of Copenhagen(exited)
Herlev University Hospital(exited)
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 294 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (527 %) | (127 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (620 %) | (127 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.